Patients were randomly assigned in a @:@ ratio with dynamic allocation and minimisation , stratified by biological subtype and Ki-@ level to receive , at the same time as the backbone regimens , either carboplatin ( AUC @ -LSB- @ for the first @ patients -RSB- once a week ) or no carboplatin .